Cytosolic phospholipase A2 · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Cytosolic phospholipase A2 shows clinical signal disease relevance led by osteoarthritis. 1 more disease program remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P47712. Start with osteoarthritis, then reuse UniProt P47712 as the stable protein anchor across project notes and exports.
Start with osteoarthritis, then reuse UniProt P47712 as the stable protein anchor across project notes and exports.
Cytosolic phospholipase A2 shows clinical signal disease relevance led by osteoarthritis. 1 more disease program remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with osteoarthritis because it currently carries clinical signal support. Linked drugs include GIRIPLADIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyCytosolic phospholipase A2
Review this target as Cytosolic phospholipase A2, mapped to UniProt P47712. Sequence length is 749 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Cytosolic phospholipase A2 as ChEMBL target CHEMBL3816, mapped to UniProt P47712. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Cytosolic phospholipase A2 is the right protein anchor across sources, using UniProt P47712 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why osteoarthritis is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Cytosolic phospholipase A2 |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P47712 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Cytosolic phospholipase A2 |
| UniProt Accession | P47712 |
| Component Type | Protein |
| Sequence Length | 749 aa |
Cytosolic phospholipase A2
Review this target as Cytosolic phospholipase A2, mapped to UniProt P47712. Sequence length is 749 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Cytosolic phospholipase A2 shows clinical signal disease relevance led by osteoarthritis. 1 more disease program remain visible in the same review block.
Start review with osteoarthritis because it currently carries clinical signal support. Linked drugs include GIRIPLADIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL272342 | 9.27 | IC50 | 0.54 | Clinical |
| CHEMBL443834 | 9.05 | IC50 | 0.9 | Preclinical |
| CHEMBL426665 | 8.96 | IC50 | 1.1 | Preclinical |
| CHEMBL441326 | 8.74 | IC50 | 1.8 | Preclinical |
| CHEMBL9161 | 8.68 | IC50 | 2.1 | Preclinical |
| CHEMBL267258 | 8.51 | IC50 | 3.1 | Preclinical |
| CHEMBL484413 | 8.3 | IC50 | 5.0 | Preclinical |
| CHEMBL8973 | 8.28 | IC50 | 5.3 | Preclinical |
| CHEMBL451642 | 8.22 | IC50 | 6.0 | Preclinical |
| CHEMBL8970 | 8.21 | IC50 | 6.2 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 68 | 250 | 6.2 |
| assay format | 14 | 61 | 6.7 |
| cell-based format | 9 | 11 | 5.1 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 3 | 15 | 6.7 |